Prescription Drug Patents Ending

In the next five years, there are many high-cost Brand Name prescription drugs that are coming off patent.

This is a positive development, but it is also important to note that in the first several months, or even first few years, the new generic may be expensive compared to the net cost of a brand or other alternatives. 

In fact, 50% of these generics continue to remain high cost after 18 months!

2011	2012	2013	2014	2015
Annual Sales
$ 20 Billion	$32.5 Billion	$8.6 Billion	$ 16 Billion	$7.5 Billion
§  Caduet §  Levaquin §  Lipitor §  Patanol §  Tricor §  Xalatan §  Zyprexa	§  Actos §  Avandia §  Avapro §  Detrol LA §  Diovan §  Geodon §  Lexapro §  Plavix §  Provigil §  Seroquel §  Singulair §  Viagra	§  AcipHex §  Avodart §  Cymbalta §  Niaspan §  OxyContin §  Propecia §  Sustiva	§   Actonel §  Arthrotec §  Asacol §  Avelox §  Celebrex §  Evista §  LoEstrin FE §  Lunesta §  Nexium §  Yasmin	§  Abilify §  Aggrenox §  Androgel §  Avodart §  Axert §  Gleevec §  Namenda §  Ortho Evra §  Ortho TriCylen Lo §  Sustiva §  Welchol

This would be a good time to examine the alternatives with your Insurance Carrier and/or Pharmacy Benefit Manager.  It may also be a good time to structure your Rx program accordingly.